Cambridge Healthtech Institute’s Fifth Annual
Optimizing Protein Expression
Enhancing Expression Systems
Part of the 11th Annual PEGS: the essential protein engineering summit
May 6-7, 2015 | Seaport World Trade Center | Boston, Ma

Preliminary Agenda 

When expressing protein, there are a variety of expression systems to choose from. CHO is seen as the ‘king’ in the industry, but does it meet all needs of rapid production and budget constraints? This meeting will explore Optimizing Protein Expression through understanding and enhancing expression systems, and will especially focus on CHO cells and other mammalian systems, E.coli and yeasts. Other host systems, such as baculovirus and algae, will be touched on as well. Along with case studies, the meeting will feature experts who reveal the underlying mechanisms and insights into the varying systems in order to enhance protein expression. Comparing and contrasting systems will also be featured to provide greater understanding of how these systems function within the context of the results achieved.


Enhanced Protein Production in Mammalian and Insect Cells by Precise Genome Editing with the Cas9/CRISPR Technology

Lorenz Mayr, Ph.D., Vice President, Reagents & Assay Development, AstraZeneca

Using the Endoplasmic Reticulum as a Physiological Test Tube: Predicting Poor Solution Behaviors of mAb Clones during Transient Expression in cellulo 

Haruki Hasegawa, Ph.D., Principal Scientist, Therapeutic Discovery, Amgen, Inc.


microRNAs: Targets for Improving CHO Cells as Protein Factories

Colin Clarke, Ph.D., Bioinformatics Research Fellow, National Institute for Cellular Biotechnology (NICB), Dublin City University

GeneOptimizer Program-Assisted cDNA Reengineering Enhances sRAGE Autologous Expression in Chinese Hamster Ovary Cells

Li Lin, Ph.D., Senior Research Fellow, Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health (NIH)


E. coli and CHO Protein Expression Technology at Genentech

Dorothea E. Reilly, Ph.D., Associate Director, Early Stage Cell Culture, Genentech, Inc. – A Member of the Roche Group

Differences in Clearance of Recombinant Proteins Expressed in HEK and CHO Cells

Mengmeng Wang, Ph.D., Principal Scientist, PDM, Pfizer, Inc.

A Comparison of Two Methods for the Transient Expression and Purification of Ebola Glycoprotein from HEK-293 and CHO Cells

Christopher W. Kemp, Ph.D., President, Kempbio, Inc.

Cell Line Development Tool Box for Expression: E. coli, HEK293, CHO, Insect Cells

Sam Ellis, Vice President, Thomson Instrument Company

Optimizing Antibody & Vaccine Production in CHO, Insect, and Other Mammalian Cells with Scalable Flow Transfection

Weili Wang, Ph.D., Principal Scientist, Protein Production, MaxCyte


Hijacking E. coli’s Heat-Shock Response Enhances Recombinant Protein Production

Xin Zhang, Ph.D., Burroughs Wellcome–CASI Fellow, Scripps Research Institute

Baculovirus Expression of HSV-2 Vaccine Antigens: Challenges and Solutions

Rajiv Gangurde, Ph.D., Associate Director, Protein Production, Genocea Biosciences, Inc.


Production of Antibody Toxin Fusions as a Next-Generation Targeted Therapy Using Algae Chloroplast

Miller Tran, Ph.D., Senior Scientist, Lead Discovery, Verdant Therapeutics, Inc.

Double Digit-Titers and High Product Quality of Nanobodies® using Pichia pastoris 

Peter Schotte, Ph.D., Section Head, CMC - Host Creation, Ablynx nv

Optimizing the Quality of IgGs Produced in Yeast – Removal of Glycans at a Non-Consensus Asparagine Residue

Juergen Nett, Ph.D., Senior Principal Scientist, Adimab, LLC

For more details on the conference, please contact:
Mary Ruberry
Senior Conference Director
Cambridge Healthtech Institute
T: 781-972-5421

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471